Literature DB >> 1617079

Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).

J Liñares1, R Pallares, T Alonso, J L Perez, J Ayats, F Gudiol, P F Viladrich, R Martin.   

Abstract

From January 1979 to December 1990 we studied the susceptibility of 1,492 pneumococcal strains isolated from adult patients in Bellvitge Hospital, Barcelona, Spain, to nine antimicrobial agents. Among clinically significant pneumococci, the incidence of penicillin-resistant strains increased from 4.3% in 1979 to 40% in 1990, and that of erythromycin-resistant strains also rose from 0% in 1979 to 9.4% in 1990. On the other hand, the incidence of strains resistant to tetracycline decreased from 76.1% to 37.6%, as did that of chloramphenicol-resistant strains, from 56.5% to 29.4%. The incidence of co-trimoxazole-resistant strains was about 40% throughout the study. Even more alarming was the finding that about 70% of penicillin-resistant strains showed multiple resistance to non-beta-lactam antibiotics. All pneumococci were susceptible to vancomycin, and all but six were susceptible to rifampin. We observed that isolates from cerebrospinal fluid and the respiratory tract were significantly more resistant to penicillin than were isolates from blood. The majority of strains (95%) belonged to serogroups or serotypes included in the 23-valent pneumococcal vaccine and 77.6% of penicillin-resistant strains belonged to groups 23, 6, 9, and 19.

Entities:  

Mesh:

Year:  1992        PMID: 1617079     DOI: 10.1093/clinids/15.1.99

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  59 in total

1.  Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice.

Authors:  E Azoulay-Dupuis; V Rieux; M Muffat-Joly; J P Bédos; E Vallée; C Rivier; R Isturiz; C Carbon; P Moine
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Current Concepts of Therapy for Otitis Media.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

3.  Geographic distribution and clonal diversity of Streptococcus pneumoniae serotype 1 isolates.

Authors:  Angela B Brueggemann; Brian G Spratt
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

4.  Genetic relatedness of recently collected Spanish respiratory tract Streptococcus pneumoniae isolates with reduced susceptibility to amoxicillin.

Authors:  E Pérez-Trallero; J M Marimón; A González; C García-Rey; L Aguilar
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

5.  Increase of the M phenotype among erythromycin-resistant Streptococcus pneumoniae isolates from Spain related to the serotype 14 variant of the Spain9V-3 clone.

Authors:  C Ardanuy; A Fenoll; S Berrón; L Calatayud; J Liñares
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

7.  In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

8.  Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae isolated from patients with community-acquired pneumonia and molecular analysis of multidrug-resistant serotype 19F and 23F strains in Japan.

Authors:  L Qin; H Watanabe; H Yoshimine; H Guio; K Watanabe; K Kawakami; A Iwagaki; H Nagai; H Goto; T Kuriyama; Y Fukuchi; T Matsushima; S Kudoh; K Shimada; K Matsumoto; T Nagatake; T Mizota; K Oishi
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

9.  Comparative activity of the new fluoroquinolone Bay y3118 against 177 penicillin susceptible and resistant pneumococci.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

10.  Current usefulness of procaine penicillin in the treatment of pneumococcal pneumonia.

Authors:  C Cabellos; J Ariza; B Barreiro; F Tubau; J Liñares; R Pallarés; F Manresa; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.